Browse the corpus

©2013 UpToDate ® Print Email Diagnostic criteria: accelerated phase of chronic myelogenous leukemia MD Anderson* Sokal et al• WHOΔ PB blasts ≥15 percent PB blasts + pro ≥30 percent PB or BM blasts ≥5 percent PB or BM blasts 10-19 percent PB baso ≥20 percent PB basophils ≥20 percent PB basophils ≥20 percent Platelets <100,000/µL not related totherapy Thrombocytopenia, not related to therapy Platelets <100,000/µL, unrelated totherapy Cytogenetic evolution Cytogenetic evolution Cytogenetic evolution Platelets >1 million/µL despiteadequate therapy Platelets >1,000,000/µL unresponsiveto therapy Marrow collagen fibrosis Anemia, unrelated to Rx Progressive splenomegaly Progressive splenomegaly and increasing WBCunresponsive to therapy WBC doubling time <5 days Unexplained fever Pelger-Huett-like neutrophils, nucleated RBCs,megakaryocyte fragments WHO: World Health Organization; PB: peripheral blood; BM: bone marrow; pro: promyelocytes; baso: basophils; WBC: white blood cell count; RBC: red blood cells. * Kantarjian, HM, et al. Cancer 1988; 61:1441. • Sokal, JE, et al. Semin Hematol 1988; 25:49. Δ Vardiman, JW, et al. Blood 2002; 100:2292. For each of the three sets of criteria, the accelerated phase of chronic myelogenous leukemia is diagnosed if one or more of the listed features is present. Adapted from O'Dwyer, ME, et al. Blood 2002; 100:1628.